sorafenib has been researched along with Abnormal Karyotype in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mori, M; Sprague, J | 1 |
1 other study(ies) available for sorafenib and Abnormal Karyotype
| Article | Year |
|---|---|
The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics.
Topics: Abnormal Karyotype; Antineoplastic Agents; Benzenesulfonates; Cytogenetic Analysis; Drug Resistance, Neoplasm; Erythroid Cells; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Erythroblastic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences; Time Factors; Treatment Outcome | 2012 |